Food and Drug Administration Drug Safety Podcast
FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns
- Autor: Podcast
- Narrador: Podcast
- Editora: Podcast
- Duração: 0:02:00
- Mais informações
Informações:
Sinopse
Listen to an audio podcast of the 6/1/22 for Ukoniq . FDA withdrew its approval for the cancer medicine Ukoniq (active ingredient umbralisib) due to safety concerns. Ukoniq was approved to treat two specific types of lymphoma: marginal zone lymphoma (MZL) and follicular lymphoma (FL)
